Study of cell markers as a prognostic factor in dogs with intranasal neoplasia treated with chemotherapy and rhinotomy

• Grant number: 13/12113-4
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2013
• End date: September 30, 2015
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Angelo João Stopiglia
• Grantee: Angelo João Stopiglia
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

The nasal and sinonasal neoplasms represent 59-82% of cases of tumors in the respiratory tract of dogs, 80% are malignant. The visualization of these neoplasms in nasal cavity, is possible by rhinoscopy, and tomographic image upside assesses the extent, however, is the histopathological analysis of biopsy which concludes the diagnosis. The treatment is still limited and discussed. The objective of this study is to evaluate the contribution and effectiveness of treatment of malignant neoplasms in the nasal cavity of dogs using chemotherapy alone or associated with rhinotomy, and jointly analyze the role of cell markers as prognostic indicators through immunohistochemical study classifying these patients about the staging and survival after treatment. Will be used in dogs treated FMVZ / USP, with clinical manifestations compatible with nasal disease, underwent rhinoscopy with collection of biopsy and CT head. Animals with histopathology confirmed by nasal malignant neoplasm of mesenchymal or epithelial origin shall be submitted to chemotherapy agent or in combination with rhinotomy. The results will be evaluated following the staging systems according to CT imaging and rhinoscopy, after the 28th day of the eighth session of chemotherapy, ie interspersed four applications of each drug. The prognosis of these patients will be evaluated according to the expression of cellular markers COX 2, VGF, EGFR, p53, PCNA and Ki67, correlating with disease progression and response to treatment. The quality of life will also be analyzed by specific questionnaire. (AU)